Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013)

Diagnostic Microbiology and Infectious Disease

Volumn 85, Issue 3, 2016, Pages 352-355

  Flamm, Robert K ^a   Castanheira, Mariana ^a   Streit, Jennifer M ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Acinetobacter baumannii; Minocycline; Tetracycline

Indexed keywords

AMIKACIN; CEFTAZIDIME; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; BROTH DILUTION; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; DOSE RESPONSE; EUROPE; EXTENSIVELY DRUG RESISTANT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; SOUTHERN EUROPE; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HEALTH; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; GLOBAL HEALTH; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STENOTROPHOMONAS MALTOPHILIA;

EID: 84963985258     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.03.019     Document Type: Article

References (29)

1. Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., Quale, J., Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 59 (2015), 1802–1805.
2. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
3. Castanheira, M., Mendes, R.E., Jones, R.N., Update on Acinetobacter spp.: mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis 59:Suppl. 6 (2014), S367–S373.
4. Chopra, I., Roberts, M., Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65 (2001), 232–260.
5. Clinical and Laboratory Standards Institute, M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition Wayne, 2015, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute, M100-S25. Performance standards for antimicrobial susceptibility testing: 25th informational supplement, 2015, CLSI, Wayne, PA.
7. Draper, M.P., Weir, S., Macone, A., Donatelli, J., Trieber, C.A., Tanaka, S.K., et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 58 (2014), 1279–1283.
8. ECDC, Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011–2012. Available at http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf, 2013 [Accessed March 2016].
9. Esposito, S., Gioia, R., De Simone, G., Noviello, S., Lombardi, D., Di Crescenzo, V.G., et al. Bacterial epidemiology and antimicrobial resistance in the surgery wards of a large teaching hospital in southern Italy. Mediterr J Hematol Infect Dis, 7, 2015, e2015040.
10. EUCAST, Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. Available at http://www.eucast.org/clinical_breakpoints/, 2015 [Accessed January 2015].
11. Fritsche, T.R., Sader, H.S., Jones, R.N., Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: Results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagn Microbiol Infect Dis 61 (2008), 86–95.
12. Gordon, N.C., Png, K., Wareham, D.W., Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 54 (2010), 5316–5322.
13. Grassi, G.G., Tetracyclines - extending the atypical spectrum. Int J Antimicrob Agents 3 (1993), S31–S46.
14. Hujer, K.M., Hujer, A.M., Hulten, E.A., Bajaksouzian, S., Adams, J.M., Donskey, C.J., et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter spp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 50 (2006), 4114–4123.
15. Jones, R.N., Guzman-Blanco, M., Gales, A.C., Gallegos, B., Castro, A.L., Martino, M.D., et al. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz J Infect Dis 17 (2013), 672–681.
16. Jones, R.N., Wilson, M.L., Weinstein, M.P., Stilwell, M.G., Mendes, R.E., Contemporary potencies of minocycline and tetracycline HCL tested against gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria. Diagn Microbiol Infect Dis 75 (2013), 402–405.
17. Li, J., Rayner, C.R., Nation, R.L., Owen, R.J., Spelman, D., Tan, K.E., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50 (2006), 2946–2950.
18. Li, H., Liu, F., Zhang, Y., Wang, X., Zhao, C., Chen, H., et al. Evolution of carbapenem-resistant Acinetobacter baumannii revealed through whole-genome sequencing and comparative genomic analysis. Antimicrob Agents Chemother 59 (2015), 1168–1176.
19. Macone, A.B., Caruso, B.K., Leahy, R.G., Donatelli, J., Weir, S., Draper, M.P., et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58 (2014), 1127–1135.
20. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
21. Migliavacca, R., Espinal, P., Principe, L., Drago, M., Fugazza, G., Roca, I., et al. Characterization of resistance mechanisms and genetic relatedness of carbapenem-resistant Acinetobacter baumannii isolated from blood, Italy. Diagn Microbiol Infect Dis 75 (2013), 180–186.
22. Oliveira, M.S., Prado, G.V., Costa, S.F., Grinbaum, R.S., Levin, A.S., Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61 (2008), 1369–1375.
23. Perez, F., Hujer, A.M., Hujer, K.M., Decker, B.K., Rather, P.N., Bonomo, R.A., Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007), 3471–3484.
24. Sutcliffe, J.A., O'Brien, W., Fyfe, C., Grossman, T.H., Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57 (2013), 5548–5558.
25. Talbot, G.H., Bradley, J., Edwards, J.E. Jr., Gilbert, D., Scheld, M., Bartlett, J.G., Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006), 657–668.
26. Tuon, F.F., Rymsza, A.M., Penteado-Filho, S.R., Pilonetto, M., Arend, L.N., Levin, A.S., Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?. J Infect 62 (2011), 246–249.
27. Tygacil® Package Insert, Wyeth Pharmaceuticals, Philadelphia, PA. Available at www.tygacil.com, 2014 [Accessed January 25, 2016].
28. Yong, D., Shin, H.B., Kim, Y.K., Cho, J., Lee, W.G., Ha, G.Y., et al. Increase in the prevalence of carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-typhoidal Salmonella species in Korea: A KONSAR study conducted in 2011. Infect Chemother 46 (2014), 84–93.
29. Yoon, E.J., Courvalin, P., Grillot-Courvalin, C., RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother 57 (2013), 2989–2995.